MinervaX raises upsized EUR 47.4M (USD 57M) Series B to advance its novel Group B Streptococcus vaccine through mid-stage clinical trials

MinervaX, a privately held Danish biotechnology
company developing a novel vaccine against Group B Streptococcus (GBS), announced today that it
has raised an upsized EUR 47.4 million Series B financing. The round included new investors Sanofi
Ventures, Wellington Partners, Adjuvant Capital, and Industrifonden, along with existing investors
Novo Holdings REPAIR Impact Fund, Sunstone Life Science Ventures, and LF Investment. Proceeds will
advance the clinical development of MinervaX’s novel GBS vaccine through Phase II clinical trials, as
well as manufacturing and regulatory preparation for Phase III.

Read more….

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...